BioCentury | Apr 21, 2020
Product Development

Trio of tactics to target COVID-19 hyperinflammation

Three companies announced COVID-19 programs Monday aimed at blocking the excessive inflammatory response seen in severe cases. Alexion unveiled a global program for its C5 inhibitor Ultomiris, while 4D pharma moved its live biotherapeutic therapy...
BioCentury | May 8, 2019
Financial News

CRO Viva raises $193.9 million in Hong Kong IPO

...active applications for listing on the biotech chapter including Shanghai Henlius Biotech Inc. (Shanghai, China), MicuRx...
BioCentury | Mar 29, 2019
Targets & Mechanisms

Next-wave targets at AACR 2019 start filling the blanks in the tumor microenvironment

New and emerging targets at AACR 2019 show cancer researchers are gaining granularity on how to manipulate the tumor microenvironment, a top priority goal for the field. The targets point to emerging strategies for modulating...
BioCentury | Feb 8, 2019
Financial News

Frazier-backed Recida launches with $8.5M series A

...of Japan to RC-01 from Fujifilm Toyama Chemical Co. Ltd. (Tokyo, Japan) and subsequently granted MicuRx...
...slated to be completed this year. Recida Therapeutics Inc., Menlo Park, Calif. Shannon Lehnbeuter MRX-10 (RC-01) Frazier Healthcare Partners MicuRx...
BioCentury | Jan 12, 2019
Finance

Warning: cash needed

...1/7/19 Up to $150M Ph I Poseida Therapeutics Inc. 1/4/19 Up to $115M Ph I MicuRx...
BioCentury | Jan 9, 2019
Financial News

MicuRx refiles for Hong Kong listing

...Hong Kong IPOs" ). In November, MicuRx began a Phase II trial of contezolid acefosamil (MRX-4...
...and skin structure infections (ABSSSI) caused by Gram-positive bacteria. Contezolid acefosamil is a prodrug of MicuRx's...
...complicated skin and soft tissue infections. MicuRx Pharmaceuticals Inc., Foster City, Calif. Elizabeth S. Eaton contezolid (MRX-1, mrx-I) MicuRx...
BioCentury | Sep 13, 2018
Clinical News

4D's MRx0004 improves inflammation in asthma model

4D Pharma plc (LSE:DDDD) said once-daily oral MRx0004 protected against airway inflammation by decreasing infiltration of both neutrophils and eosinophils in the lung bronchoalveolar lavage fluid of a house dust mite mouse model of severe...
BioCentury | Aug 8, 2018
Financial News

BeiGene dips slightly in Hong Kong debut

...company Innovent Biologics Inc. (Suzhou, China), vaccine developer CanSino Biologics Inc. (Tianjin, China), antibiotics company MicuRx...
BioCentury | Aug 4, 2018
Finance

Hong Kong’s first wave

...Inc. 7/3/2018 Ph II Stealth BioTherapeutics Corp. 7/3/2018 Ph III Innovent Biologics Inc. 6/28/2018 Registration MicuRx...
BioCentury | Aug 3, 2018
Financial News

Ascletis ends first trading week on downturn

...play Innovent Biologics Inc. (Suzhou, China), vaccine developer CanSino Biologics Inc. (Tianjin, China), antibiotics company MicuRx...
Items per page:
1 - 10 of 229